Articles related to Hematology/Oncology

Retrospective analysis of pediatric cancer survivors identified low overall CHIP prevalence, with antimetabolite therapy and methotrexate exposure emerging as the strongest treatment-associated signals.

Retrospective analyses presented at SABCS 2025 associated GLP-1 receptor agonist use with weight loss, mortality, and recurrence signals in breast cancer cohorts, with effects on endocrine therapy tolerability also observed.

Invasive mucinous adenocarcinoma carries elevated NRG1 fusion burden that standard DNA-based sequencing reliably misses, while an FDA-approved targeted therapy now exists for confirmed cases.

Daraxonrasib produced 13.2-month median overall survival versus 6.7 months with chemotherapy in 501 previously treated metastatic pancreatic ductal adenocarcinoma patients in the phase 3 RASolute 302 trial.

Osimertinib plus datopotamab deruxtecan produced 20.5-month median duration of response at the 6 mg/kg dose in EGFR-mutated NSCLC after first-line osimertinib progression in the ORCHARD platform substudy.

DAGO2 produced 3-year overall survival of 52% versus 35% with CPX-351 in older patients with non-adverse-risk AML in a 439-patient randomized comparison.